港股異動 | 中國飛鶴(6186.HK)漲逾6% 花旗上調公司目標價至27.2港元
格隆匯2月2日丨中國飛鶴(6186.HK)持續拉昇,現報24.5港元,漲幅6.06%,最新總市值2188.67億港元。花旗研報指,根據市場調查數據,中國飛鶴市場份額持續增長,由去年第三季的17.12%擴大至第四季的17.3%,其中線下市場份額亦由第三季的19%進一步上升至20%,線上市佔率於上季保持在約10%的水平,令全年市場份額增長4個百分點至15.6%。維持公司2020至2022年核心淨利潤增長45%、31%及24%的預測,將目標價由22.1港元上調至27.2港元,評級“買入”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.